Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

AstraZeneca Wins New Approval for Asthma Inhaler

By Pharmaceutical Processing | March 2, 2009

WASHINGTON (AP) — British pharmaceutical firm AstraZeneca PLC said Friday it received approval to market its asthma drug for an additional use, boosting its ability to compete with competitor GlaxoSmithKline. The Food and Drug Administration approved Symbicort to treat chronic bronchitis and emphysema, which causes coughing, wheezing and shortness of breath. The additional approval means Symbicort is now available to treat both asthma and chronic bronchitis. That’s the same indication as Advair, the blockbuster drug from rival GlaxoSmithKline that dominates the market for inhalable respiratory drugs. Advair is the British drugmaker’s top product and was the third best-selling prescription in the U.S. for 2007 at $4.3 billion, according to research firm IMS Health. Both Advair and Symbicort come in inhalers containing two ingredients: one that relaxes muscles around stressed airways and another that reduces inflammation. AstraZeneca has struggled to take U.S. market share away from Glaxo since Symbicort was launched in 2007. However, AstraZeneca recently reported about one-fifth of newly treated asthma patients receive a Symbicort prescription. The company estimates about 12 million U.S. patients have chronic bronchitis. The disease, also known as chronic obstructive pulmonary disease, is the fourth leading cause of death in the U.S. In a separate development Friday, AstraZeneca PLC said the FDA asked for additional information about the company’s application to market Seroquel XR extended release tablets for anxiety.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE